Comparison
Compare BPC-157, TB-500, GHK-Cu and KPV
A useful comparison starts with the tested preparation and the setting in which it acted.
Experimental settings
A single ranking erases too many distinctions between these compounds. Their strongest examples ask different questions: healing of a transected rat tendon, neurological outcomes after rat stroke, topical skin changes and inflammation in mouse colon tissue. Even a consistent result within each setting would leave the comparison between settings unresolved.
The table is therefore a set of separate research situations. It helps locate a claim before asking how much authority to give it.
Molecule, setting and clinical reach
| Compound | Tested material and setting | Human evidence |
|---|---|---|
| BPC-157 | Synthetic gastric peptide; tendon, gut and vascular models, largely in rodents | Three small pilots in the 2025 review; large rigorous trials lacking |
| TB-500 | Short Ac-LKKTETQ fragment; most efficacy work tests full-length thymosin beta-4 | A 40-volunteer safety study of the full protein; completed controlled fragment trials absent |
| GHK-Cu | Copper-bound tripeptide; skin matrix and topical formulations | Small topical studies; systemic human pharmacokinetics unvalidated |
| KPV | Alpha-MSH tail fragment; cell systems and mouse colitis, including engineered carriers | Preclinical literature; published human trials absent |
Receptors, partners and dose response
The dependencies differ. BPC-157's cell and animal VEGFR2 experiments linked vessel-growth effects to receptor internalization. KPV's MC1R-deficient mouse result showed that particular receptor could be deficient while an anti-inflammatory effect persisted. These experiments probe different systems; they offer no common score for molecular power.
GHK-Cu brings copper coordination into the question, as described in the skin-regeneration review. The thymosin beta-4 stroke experiment adds the amount tested: neurological benefit at 2 and 12 mg/kg in rats, with no significant benefit at 18 mg/kg. I regard these dependencies as the substance of the research. Removing them would make the claims broader and much less interesting.
Approval, prescriptions and sport
None of these compounds has FDA or EMA approval as a systemic medicine. GHK-Cu also has a separate, established place as the cosmetic ingredient Copper Tripeptide-1. Clinical prescribing and research-labelled supply coexist; a compounded preparation has no FDA approval, and a prescription decision belongs to a licensed provider.
BPC-157 and TB-500 are explicitly WADA-prohibited, with BPC-157 under S0. KPV has no established compound-specific WADA classification in this record. Silence about a name cannot settle sporting eligibility. Questions about an individual's treatment or eligibility require the appropriate professional assessment.
For narrower questions about the molecules, the FAQ covers growth hormone, anti-aging language and the difference between GHK and its copper complex.